1 enter (ratio, 2.37 vs 1.43; P = .06) and the
multicenter (
2.03 vs 0.91; P = .14) cohorts.
2 Multicenter (
8 sites) retrospective review of medical re
3 METHODS AND Subjects in the prospective,
multicenter ADAPT-DES study (Assessment of Dual Antiplat
4 ual follow-up visits (every 6 months) in the
multicenter Advanced Imaging for Glaucoma Study.
5 matched case-control study nested within the
multicenter African RTS,S/AS01E phase 3 trial.
6 rd Kaslow et al. described the launch of the
Multicenter AIDS Cohort Study (MACS), a cohort study of
7 tudy of 558 HIV-infected men enrolled in the
Multicenter AIDS Cohort Study between 1990 and 2010, the
8 a and sera of 722 participants in the German
Multicenter Allergy Study, a birth cohort started in 199
9 Secondary analysis of a
multicenter,
block-randomized clinical trial.
10 nsecutive patients enrolled in any 1 of 9 US
multicenter cancer treatment trials were invited to self
11 Participants in
multicenter cancer trials are willing and able to report
12 This was a
multicenter case series of 3 patients with confirmed tis
13 Retrospective, observational,
multicenter case series review.
14 Prospective,
multicenter case series.
15 Retrospective,
multicenter case series.
16 Single-arm, open-label,
multicenter clinical study.
17 Randomized, controlled,
multicenter clinical trial.
18 Well-controlled
multicenter clinical trials are ongoing and data are awa
19 e way of generating reliable data in allergy
multicenter clinical trials.
20 ing were reviewed to identify 6 large-scale,
multicenter clinical trials.
21 d difficulties associated with validation in
multicenter clinical trials.
22 ected pregnant women require confirmation in
multicenter clinical trials.
23 nd this makes it difficult to perform large,
multicenter clinical trials.
24 An international,
multicenter cohort of R0 resected HCC patients were cate
25 lescent AIDS Clinical Trials (IMPAACT) P1074
multicenter cohort studies (March 2007 through April 201
26 Retrospective,
multicenter cohort study of 5-year cancer survivors diag
27 This was a
multicenter cohort study of consecutive ALF patients fro
28 Patients' Health Status) is an observational
multicenter cohort study that enrolled 4062 patients age
29 In this retrospective
multicenter cohort study, 217 patients 6 years and older
30 In a prospective,
multicenter cohort study, we found that patients with ir
31 Retrospective
multicenter cohort study.
32 To validate the CHOP ROP model in a
multicenter cohort that is large enough to obtain a prec
33 Findings were validated in a separate
multicenter cohort via prespecified analysis, blinded pe
34 and 246 included in a unicenter cohort and a
multicenter cohort.
35 ence Center for PIDs initiated a prospective
multicenter cohort: the French Childhood Immune Deficien
36 Materials and Methods Two
multicenter cohorts (n = 991) were used for training and
37 Multicenter collaborative quality improvement efforts ma
38 In this
multicenter comparison of palliative PDA stent and BT sh
39 A
multicenter consecutive case series non-interventional s
40 Prospective, randomized,
multicenter,
controlled clinical trial.
41 rom 191 obese, nondiabetic patients within a
multicenter,
controlled dietary intervention.
42 butter on cardiometabolic risk factors.In a
multicenter,
crossover, randomized controlled trial, 92
43 After 5
multicenter design-test-evaluate-redesign phases with a
44 Prospective,
multicenter diagnostic evaluation and validation in acad
45 In a prospective
multicenter diagnostic study enrolling unselected patien
46 Purpose To determine, in a
multicenter double-blinded placebo-controlled trial, whe
47 Patients and Methods In this
multicenter,
double-blind, phase III trial, patients wer
48 This
multicenter,
double-blind, placebo-controlled RCT was po
49 In this
multicenter,
double-blind, placebo-controlled trial, we
50 We conducted a phase 2,
multicenter,
double-blind, placebo-controlled, multiple-
51 We conducted a phase 1b,
multicenter,
double-blind, placebo-controlled, multiple-
52 Multicenter,
double-blind, randomized clinical trial inc
53 In this
multicenter,
double-blind, randomized, placebo-controlle
54 In this
multicenter,
double-blind, randomized, placebo-controlle
55 lysis of Mycotic Ulcer Treatment Trial II, a
multicenter,
double-masked, placebo-controlled randomize
56 A
multicenter,
double-masked, randomized noninferiority cl
57 n in Severe Sepsis study, a Spanish national
multicenter educational intervention to improve antibiot
58 We used a prospective
multicenter (
Emory University Hospital, Brigham and Wome
59 Pierce et al. report on a
multicenter evaluation of the modified carbapenem inacti
60 A prospective,
multicenter,
evaluator-blinded, randomized clinical tria
61 This is an exploratory analysis of the
multicenter FinXX randomized clinical trial that accrued
62 There is an unmet need for a longitudinal
multicenter,
global registry of patients with HFpEF to m
63 Materials and Methods This prospective
multicenter HIPAA-compliant study had institutional revi
64 risk and were moderately calibrated in this
multicenter HIV cohort.
65 Materials and Methods In the Prospective
Multicenter Imaging Study for Evaluation of Chest Pain (
66 comparative effectiveness trial (Prospective
Multicenter Imaging Study for Evaluation of Chest Pain [
67 In the PROMISE trial (Prospective
Multicenter Imaging Study for Evaluation of Chest Pain),
68 This
multicenter (
India and Africa), comparative, parallel-gr
69 2 large consecutive prospective, randomized,
multicenter,
intensive chemotherapy trials (AML96, AML20
70 A retrospective, observational,
multicenter,
international study was performed during 20
71 istologic evaluations performed as part of a
multicenter investigation.
72 We conducted a
multicenter longitudinal cohort study of 602 patients un
73 Observational and Nutrition Study (BONUS), a
multicenter,
longitudinal, observational cohort study, w
74 Patients and Methods A
multicenter,
longitudinal, prospective study was conduct
75 Multicenter masked clinical trial.
76 The primary objective of this international,
multicenter,
multidisciplinary clinical study was to dev
77 red Treatment in Chronic Heart Failure) is a
multicenter,
multinational, prospective, observational s
78 Purpose To determine in a large
multicenter multireader setting the interreader reliabil
79 t Screening Program), an ethically approved,
multicenter,
multireader, retrospective reading study, b
80 Multicenter,
national cohort study.
81 METHODS AND Using a
multicenter,
national Veterans Affairs (VA) cohort, all
82 n the Left Ventricle) study is a prospective
multicenter non-randomized trial assessing the safety an
83 Three pragmatic
multicenter,
nonblinded randomized clinical trials on th
84 Multicenter,
nonrandomized registry of 1661 patients at
85 METHODS AND A prospective,
multicenter,
nonrandomized, open-label, single-arm study
86 Blinded, prospective
multicenter observational clinical trial following an Fo
87 This investigation was a cross-sectional,
multicenter observational study in the setting of the HC
88 This was a multinational prospective
multicenter observational study over 3 months of all pat
89 Prospective
multicenter observational study.
90 t of 328 patients enrolled in a prospective,
multicenter,
observational study within 3 months after d
91 is a prospective, single-arm, multinational,
multicenter,
observational study.
92 We performed a
multicenter,
observational, prospective study under cond
93 PE 1-2 is a phase 3, randomized, controlled,
multicenter,
open-label clinical trial.
94 Phase IV,
multicenter,
open-label extension study.
95 This
multicenter,
open-label study evaluated the safety and e
96 We conducted a phase 2,
multicenter,
open-label study to evaluate the efficacy a
97 Phase 1/2a,
multicenter,
open-label, dose-escalation, fellow-eye-con
98 We conducted a
multicenter,
open-label, phase 2 study to evaluate the e
99 We conducted a
multicenter,
open-label, phase 3 trial to evaluate the e
100 Patients and Methods In this
multicenter,
open-label, phase III trial, 2,012 women wi
101 Transplantation, we conducted a prospective,
multicenter,
open-label, randomized phase III trial that
102 A 12-week,
multicenter,
outpatient, open-label randomized clinical
103 Cross-sectional,
multicenter paper-pencil survey on personal and work-rel
104 e surgery were prospectively enrolled in the
multicenter PARTNER (Placement of Aortic Transcatheter V
105 therapy and switched to a second in a large,
multicenter pharmacovigilance registry (n = 1,239; adali
106 A
multicenter phase 1 study was conducted to determine the
107 A
multicenter phase 2 randomized clinical trial, the Argin
108 In this
multicenter phase 2 trial, 72 patients were randomized t
109 Methods In this prospective, international,
multicenter phase II trial, 152 treatment-naive adult so
110 We conducted a
multicenter,
phase 1 study in advanced hematological mal
111 We conducted a
multicenter,
phase 1/2 study in SRSE patients to evaluat
112 rt 3 was a partially randomized, open-label,
multicenter,
phase 3 study.
113 A National Cancer Institute (NCI) sponsored,
multicenter,
phase 3, randomized clinical trial open to
114 We conducted a nonrandomized, open-label,
multicenter,
phase 4 study.
115 SAFE-MILND (NCT01500304) is a
multicenter,
phase I/II clinical trial evaluating the sa
116 -week, phase III, randomized, double-masked,
multicenter,
placebo-controlled study.
117 conducted a phase 3, randomized withdrawal,
multicenter,
placebo-controlled, double-blind trial.
118 Multicenter,
placebo-controlled, randomized trial (July
119 plane systolic excursion (MAPSE)-in a large
multicenter population of patients with reduced ejection
120 This was a
multicenter pragmatic stepped-wedge before-and-after tri
121 tient data from the prospective, real-world,
multicenter,
PREFER in AF (European Prevention of thromb
122 biomarkers in adverse events, we conducted a
multicenter prospective cohort study of 968 adults under
123 This was a
multicenter prospective cohort study of hospitals and pr
124 We conducted a
multicenter prospective cohort study of infants (age <1
125 This was a
multicenter prospective cohort study.
126 We conducted a pragmatic
multicenter prospective evaluation of the use of point-o
127 1 participants (92.4%) were included in this
multicenter prospective investigation.
128 We performed a
multicenter prospective observational study in 7 US acad
129 In a
multicenter prospective observational study involving 6
130 Multicenter prospective observational study.
131 This was a
multicenter prospective randomized trial including 143 p
132 We performed a
multicenter prospective study of 226 patients with hepat
133 c analysis of a cohort in the e-ROP Study (a
multicenter prospective telemedicine study) and the Post
134 atients treated with MT included in 2 large,
multicenter,
prospective clinical trials that evaluated
135 Multicenter,
prospective cohort study.
136 Multicenter,
prospective interventional case series.
137 the Nidek MP-1 microperimeter as part of the
multicenter,
prospective Natural History of the Progress
138 In an observational,
multicenter,
prospective study of 94 HSCT recipients we
139 terone System) is an investigator-initiated,
multicenter,
prospective, 1:1 randomized, double-blind,
140 METHODS AND In the
multicenter,
prospective, observational PARIS study (Pat
141 This
multicenter,
prospective, observational study of a quali
142 Multicenter,
prospective, open label, noncomparative, in
143 We performed a
multicenter,
prospective, open-label study to determine
144 ology of Pneumonia in the Community Study, a
multicenter,
prospective, population-based study of comm
145 uring the 2011-2012 influenza season using a
multicenter,
prospective, test-negative case-control des
146 ADVANCE (NCT01304836) was a phase 4,
multicenter,
prospectively randomized, open-label, 24-we
147 prognostic use and reproducibility across a
multicenter PSC cohort.
148 Multicenter randomized clinical trial of women with brea
149 We performed a
multicenter randomized controlled trial of 53 children (
150 collected from adult patients screened for a
multicenter randomized controlled trial was determined b
151 Patients and Methods We conducted a
multicenter randomized noninferiority trial in intermedi
152 A prospective,
multicenter randomized placebo-controlled study was cond
153 ot Study of Anti-Restenosis Treatment) was a
multicenter randomized trial designed to estimate the ef
154 We conducted a
multicenter randomized trial involving 446 patients who
155 lysis of prospectively collected data from a
multicenter randomized trial of sedation (Randomized Eva
156 This
multicenter randomized trial with 2 parallel arms (drain
157 of cognitive control and working memory in a
multicenter,
randomized (1:1 allocation), placebo-contro
158 Pooled analysis of 2
multicenter,
randomized clinical trials.
159 The ICTUS trial was a
multicenter,
randomized controlled clinical trial that i
160 Prospective, double-blind,
multicenter,
randomized controlled study.
161 nducted a prospective, investigator-blinded,
multicenter,
randomized controlled trial of an AUC-based
162 Patients and Methods This
multicenter,
randomized controlled trial was undertaken
163 We conducted a
multicenter,
randomized trial at 14 CF centers with subj
164 Multicenter,
randomized trial conducted at 120 intensive
165 asive vs minimally invasive esophagectomy, a
multicenter,
randomized trial).
166 Eighteen-month,
multicenter,
randomized, controlled clinical trial.
167 We undertook a
multicenter,
randomized, controlled trial at 31 French h
168 We conducted a
multicenter,
randomized, controlled, open-label clinical
169 We conducted two parallel, pragmatic,
multicenter,
randomized, controlled, open-label trials w
170 We conducted a
multicenter,
randomized, double-blind, placebo-controlle
171 We performed a
multicenter,
randomized, double-blind, placebo-controlle
172 A
multicenter,
randomized, double-blind, placebo-controlle
173 In this
multicenter,
randomized, double-blind, placebo-controlle
174 In this prospective,
multicenter,
randomized, double-blind, placebo-controlle
175 phase 3b visual acuity (VA) assessor-masked,
multicenter,
randomized, interventional study.
176 Disorder (INTERBED) study is a prospective,
multicenter,
randomized, noninferiority clinical trial (
177 In this double-blind,
multicenter,
randomized, parallel-group study in North A
178 Patients and Methods In this
multicenter,
randomized, phase II study, patients with a
179 In a
multicenter,
randomized, placebo (PLAC)-controlled, cros
180 In a
multicenter,
randomized, placebo-controlled, phase 3 tri
181 Phase IIb global,
multicenter,
randomized, prospective, double-masked, con
182 Multicenter,
randomized, prospective, single-masked tria
183 In this
multicenter,
randomized, registry-based, open-label clin
184 of antigen-receptor rearrangements and blind
multicenter reanalysis of flow cytometric data, resultin
185 Insights From the POST-IT and R3F Integrated
Multicenter Registries - Implementation of FFR in Routin
186 In a national,
multicenter registry study, hospitalized patients who we
187 From the TMVR
multicenter registry, procedural and clinical outcomes o
188 From the pure native AR TAVR
multicenter registry, procedural and clinical outcomes w
189 Of 25 790 ACHD patients in an international
multicenter registry, we identified all SCD cases, match
190 m May 2009 to December 2014 in a prospective
multicenter registry.
191 A
multicenter retrospective (2001-2015) chart review.
192 D-1 blockade in this setting, we conducted a
multicenter retrospective analysis of 31 lymphoma patien
193 Multicenter retrospective cohort from 1428 hospitals par
194 We performed a
multicenter retrospective cohort study of patients under
195 A
multicenter retrospective cohort study was conducted at
196 A
multicenter retrospective cohort study was performed stu
197 Retinopathy of Prematurity (G-ROP) Study (a
multicenter retrospective cohort study).
198 A
multicenter retrospective study of patients admitted wit
199 A 16-year
multicenter retrospective study.
200 METHODS AND This
multicenter,
retrospective analysis evaluated 51 continu
201 We conducted a
multicenter,
retrospective analysis of 47 984 consecutiv
202 Conclusion In this large,
multicenter,
retrospective cohort of patients with non-d
203 This is a
multicenter,
retrospective cohort study of 2 ED HCV scre
204 Methods We conducted this
multicenter,
retrospective cohort study to characterize
205 Multicenter,
retrospective cohort study.
206 International,
multicenter,
retrospective interventional cohort study.
207 A
multicenter,
retrospective study of patients infected wi
208 A
multicenter,
retrospective study was performed using the
209 This international,
multicenter,
retrospective, cohort study included adult
210 Multicenter,
retrospective, interventional case series.
211 Multicenter,
retrospective, nonrandomized clinical study
212 Multicenter,
retrospective, observational cohort study.
213 Multicenter,
retrospective, propensity-matched cohort st
214 A
multicenter,
retrospective, propensity-matched cohort st
215 r 3864 subjects aged 40 to 70 years from the
multicenter RODAM study (Research on Obesity and Diabete
216 We conducted a
multicenter,
sequential period analysis of 528,108 patie
217 rectal cancer resection in a daily practice
multicenter setting stratified for operative risk.
218 ection in Vision Impairment Due to DME)-in a
multicenter setting.
219 SMART-AF was a
multicenter,
single-arm trial evaluating the effectivene
220 This investigator-initiated,
multicenter,
single-blind, placebo-controlled crossover
221 This was a prospective, randomized,
multicenter,
single-blinded trial.
222 A
multicenter stepped wedge cluster randomized controlled
223 Comparisons to severe asthma
multicenter studies and available registries showed data
224 y of future research outputs, can facilitate
multicenter studies and meta-analyses of pooled data, an
225 Further large
multicenter studies sharing the same imaging protocols a
226 Prospective, large-scale
multicenter studies to validate the result are warranted
227 Multicenter studies using a common nutritional screening
228 In
multicenter studies, tight glycemic control targeting a
229 e-blind, placebo-controlled, parallel group,
multicenter studies.
230 ine of 680 subjects participating in a large
multicenter study (COPDGene) over approximately 5 years.
231 This
multicenter study addressed the course of disease for ea
232 This cross-sectional retrospective
multicenter study analyzed the clinical and genetic char
233 This
multicenter study assembled genome-wide genotypic and ph
234 Researchers in a recent
multicenter study developed and validated a novel progno
235 This
multicenter study evaluated cefoxitin disk diffusion for
236 andomized, double-blind, placebo-controlled,
multicenter study evaluated the effects of intravenous h
237 This randomized, double-blind,
multicenter study evaluated the effects of tumor necrosi
238 retrospective, noninterventional, national,
multicenter study in patients from the Spanish Hepa-C re
239 This
multicenter study included 911 patients from 3 LT center
240 This retrospective
multicenter study included patient data collected from J
241 This
multicenter study measured PENK in 1,908 patients with a
242 This
multicenter study of 8 EDs in the United States enrolled
243 A
multicenter study of adult patients with candidemia was
244 This was an observational
multicenter study of all consecutive adult patients diag
245 We analyzed data from a
multicenter study of endoscopic therapy to identify fact
246 Iron Overload Screening (HEIRS) Study was a
multicenter study of ethnically diverse participants tha
247 ients and Methods We performed a prospective
multicenter study of FDG-PET/CT scanning 12 weeks after
248 In a large
multicenter study of infants hospitalized with bronchiol
249 Data were collected by a large
multicenter study of sporadic retinoblastoma in which pa
250 A
multicenter study of the investigational Virtuo system (
251 This large
multicenter study provides evidence of an association be
252 This
multicenter study sought to determine Z scores for commo
253 This
multicenter study sought to evaluate the accuracy of the
254 This
multicenter study sought to prospectively evaluate a dra
255 This prospective, single-arm,
multicenter study was conducted from November 2012 to Ja
256 Within this setting of a prospective,
multicenter study with uniform GVHD prophylaxis, conditi
257 In this
multicenter study, 1182 patients hospitalized for CAP we
258 In a prospective
multicenter study, 30 consecutive patients with severe d
259 In this large,
multicenter study, patients who received cefazolin had a
260 In this
multicenter study, patients with confirmed genetic diagn
261 In this large, independently adjudicated,
multicenter study, the stent fracture rate was low and n
262 In this
multicenter study, we describe the characteristics and o
263 In the present
multicenter study, we used structural magnetic resonance
264 not previously been analyzed using a large,
multicenter study.
265 results of a larger randomized, controlled,
multicenter study.
266 fter allogeneic HCT within this prospective,
multicenter study.
267 Prospective,
multicenter study.
268 and 3 Months) is a prospective, single-arm,
multicenter study.
269 pproved this retrospective, HIPAA-compliant,
multicenter study; informed consent was waived.
270 This prospective randomized
multicenter trial block randomized patients to a restric
271 The present
multicenter trial compared 12 weeks of supervised interv
272 This phase 3 randomized, open-label,
multicenter trial compared inolimomab vs usual care in a
273 Materials and Methods This prospective
multicenter trial enrolled 296 carriers of the BRCA muta
274 uated sacituzumab govitecan in a single-arm,
multicenter trial in patients with relapsed/refractory m
275 repeatability of (18)F-FLT PET as part of a
multicenter trial involving patients with high-grade gli
276 In this
multicenter trial involving treatment-naive patients wit
277 ACT-1 is a prospective
multicenter trial of patients who have standard surgical
278 We conducted a randomized, double-blind,
multicenter trial of RIV4 (45 mug of recombinant hemaggl
279 vated the initiation of a placebo-controlled
multicenter trial of Triplex in HCT patients.
280 This prospective randomized
multicenter trial provides evidence that clinical outcom
281 Methods CATCH was a randomized,
multicenter trial that investigated tinzaparin 175 IU/kg
282 tcomes, we conducted a phase 2, prospective,
multicenter trial to test the efficacy of the addition o
283 nce in Dialysis trial, a 6-month randomized,
multicenter trial to test whether a simple, personalized
284 In this open-label,
multicenter trial with crossover design, we randomly ass
285 METHODS AND In this prospective,
multicenter trial, 169 patients underwent FFR assessment
286 In a randomized, prospective, open-label,
multicenter trial, 48 patients with severe CS complicati
287 Patients and Methods In an open-label,
multicenter trial, patients were randomly assigned to on
288 In this phase 2
multicenter trial, we evaluated the efficacy of the comb
289 ) reduced mortality from septic shock, three
multicenter trials (ProCESS, ARISE, and ProMISe) showed
290 -small cell lung cancer from the prospective
multicenter trials ACRIN 6678 (n = 34) and MK-0646-008 (
291 apeutic options in well-designed prospective
multicenter trials are needed to identify the most effec
292 Finally, two investigator-initiated
multicenter trials highlighted doxycycline and dapsone a
293 d individual patient data from 13 randomized
multicenter trials of induction and maintenance regimens
294 leukemia is leading to expanded use through
multicenter trials.
295 it is feasible to implement this approach in
multicenter trials.
296 and able to report their symptomatic AEs in
multicenter trials.
297 Results of this large, prospective
multicenter U.S. study indicate that inability to decrea
298 the Multi-Ethnic Study of Atherosclerosis, a
multicenter US study of Caucasian, African-American, His
299 cified 7-year observational follow-up of the
Multicenter Uveitis Steroid Treatment (MUST) randomized
300 The
Multicenter Uveitis Steroid Treatment (MUST) Trial and F